Breast Cancer Clinical Trial Now Enrolling New Patients
NewYork-Presbyterian/Columbia University Medical Center is now enrolling patients in a new clinical trial examining the effectiveness of laser therapy to treat early-stage breast cancer. This new research is testing a non-surgical treatment called Novilase® Interstitial Laser Therapy (ILT).
The study is testing the ability of the laser to ablate (destroy) breast cancers that are equal to or less than 2 centimeters in size. Approximately 50% of breast cancer patients are estimated to qualify for inclusion in the study.
Traditionally, early-stage breast cancers have been removed by surgery, i.e., lumpectomy, which can unfavorably affect the look and feel of the breast. Destroying the tumor with a laser may have advantages including:
- Minimal scarring
- Less chance of infection
- Much shorter recovery time
- Preservation of natural shape (i.e., cosmetic appearance) and feel of the breast.
Women with small breast cancers will undergo the ablation procedure prior to surgical excision of their breast cancers. The ablation procedure takes place in an outpatient setting, and is typically completed in 30-60 minutes.
For information about this trial, visit ColumbiaSurgery.org/news/2013/11/30/novilase-trial-enrolling-now.